EVALUATION OF HIV-SPECIFIC CD8+ T-CELL RESPONSES IN DISEASE PROGRESSION

评估疾病进展中 HIV 特异性 CD8 T 细胞反应

• 批准号: 7376273
• 负责人: Sue Ellen Abdalian
• 金额: $ 0.73万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376273
• 关键词: EVALUATION; HIV; SPECIFIC; CD8+; CELL

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will look at the HIV-1 specific CB8+T cell responses and the dominant HIV-1 genotype longitudinally among individuals identified as HLA-B*27, B*35, B*53, and/or B*57 positive through studies done in collaboration with the REACH project. Biomedical HIV-1 related data and samples are available for the time the subjects were enrolled in REACH. HIV-1 genotyping will certainly be possible from these retrospective samples and the stored PBMCs will be evaluated for usefulness in the HIV-1 specific assays. Prospectively, samples will be collected every six months over a two-year period to evaluate both HIV-1 specific CD8+T cell responses and the dominant HIV-1 genotype longitudinally. There is the potential to have data over a 9-10 year period depending on how long the subjects were enrolled in REACH. Sample Size: A total of 113 subjects were identified at former REACH/ATN clinical sites. A preliminary survey of the clinical sites estimates that about two-thirds of these subjects are still engaged in care and potentially available for this protocol. Population: Subjects who were identified as HLA Class 1 HLA-B*27, B*35, B*53, and/or B*57 positive from the REACH study will be contacted for their interest in participating in this study. Only former REACH sites in the ATN will be eligible to enroll subjects into this study. Duration: Subjects may be enrolled up to May 30, 2003, and will be followed for a total of 2 years (96 weeks). Primary Objective: Demonstrate that few CTL escape mutations occur in HIV-1 specific CB8+T cell epitopes that are HLA-B*27 abd B*57 restricted, when compared to those restriced by HLA-B*35 and B*53. Secondary Objective: Demonstrate that CD8+T cells have a high functional avidity to HLA-B*27 and B*57 bound epitopes when compared to those responding to HLA-B*35 and B*53 bound epitopes.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中出现。列出的机构是中心的机构，不一定是研究者的机构。本研究将纵向观察通过研究确定为 HLA-B*27、B*35、B*53 和/或 B*57 阳性个体的 HIV-1 特异性 CB8+T 细胞反应和主要 HIV-1 基因型与 REACH 项目合作完成。 HIV-1 生物医学相关数据和样本在受试者注册 REACH 时即可获得。从这些回顾性样本中肯定可以进行 HIV-1 基因分型，并且将评估储存的 PBMC 在 HIV-1 特异性检测中的有用性。预计，将在两年内每六个月收集一次样本，以纵向评估 HIV-1 特异性 CD8+T 细胞反应和主要 HIV-1 基因型。有可能获得 9-10 年期间的数据，具体取决于受试者参加 REACH 的时间长短。样本量：在前 REACH/ATN 临床中心共确定了 113 名受试者。对临床地点的初步调查估计，这些受试者中约有三分之二仍在接受护理，并且可能适用于该方案。人群：在 REACH 研究中被确定为 HLA 1 类 HLA-B*27、B*35、B*53 和/或 B*57 阳性的受试者，我们将联系他们是否有兴趣参与本研究。只有 ATN 中的前 REACH 站点才有资格招募受试者参加本研究。持续时间：受试者可在 2003 年 5 月 30 日之前入组，并进行总共 2 年（96 周）的随访。主要目标：证明与受 HLA-B*35 和 B*53 限制的表位相比，受 HLA-B*27 abd B*57 限制的 HIV-1 特异性 CB8+T 细胞表位中很少发生 CTL 逃逸突变。次要目标：证明与响应 HLA-B*35 和 B*53 结合表位的细胞相比，CD8+T 细胞对 HLA-B*27 和 B*57 结合表位具有高功能亲合力。